Enhancing anti-tumour efficacy with immunotherapy combinations
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
Enhancing anti-tumour efficacy with immunotherapy combinations
F Meric-Bernstam, J Larkin, J Tabernero, C Bonini - The Lancet, 2021 - Elsevier
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
Enhancing anti-tumour efficacy with immunotherapy combinations
F Meric-Bernstam, J Larkin, J Tabernero, C Bonini - THE LANCET, 2020 - iris.unisr.it
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
Enhancing anti-tumour efficacy with immunotherapy combinations
F Meric-Bernstam, J Larkin… - Lancet (London …, 2021 - pubmed.ncbi.nlm.nih.gov
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
[引用][C] Enhancing anti-tumour efficacy with immunotherapy combinations
F Meric-Bernstam, J Larkin, J Tabernero, C Bonini - The Lancet, 2021 - cir.nii.ac.jp
Enhancing anti-tumour efficacy with immunotherapy combinations.
F Meric-Bernstam, J Larkin, J Tabernero… - Lancet (London …, 2020 - europepmc.org
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
Enhancing anti-tumour efficacy with immunotherapy combinations
F Meric-Bernstam, J Larkin, J Tabernero… - The …, 2021 - mdanderson.elsevierpure.com
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …